- Previous Close
0.2750 - Open
0.2250 - Bid 0.2000 x --
- Ask 0.2100 x --
- Day's Range
0.1850 - 0.2400 - 52 Week Range
0.1100 - 0.4300 - Volume
420,032 - Avg. Volume
71,991 - Market Cap (intraday)
17.704M - Beta (5Y Monthly) 3.39
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain and Rett syndrome, and anesthesia and procedural sedation, as well as Ischemia reperfusion injury. It also develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures. In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases. Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS. The company also holds a patent and know-how license agreement with The Queen's University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology; and a license agreement with Gesval SA, as well as valuation and exclusive option agreement with Case Western Reserve University for development and commercialization for the intellectual property of ketamine for the treatment of Rett syndrome. PharmaTher Holdings Ltd. was incorporated in 2019 and is headquartered in Toronto, Canada.
www.pharmather.com--
Full Time Employees
May 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: PHRM.CN
View More
Performance Overview: PHRM.CN
Trailing total returns as of 2024-10-23, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHRM.CN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHRM.CN
View MoreValuation Measures
Market Cap
27.44M
Enterprise Value
24.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.31
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.76%
Return on Equity (ttm)
-80.35%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.12M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
2.3M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.52M